DOCS

Doximity Inc

Add to Watchlist

Advanced Chart

59.250

-1(-1.660%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

60.640

Open

60.280

VWAP

59.67

Vol

853.42K

Mkt Cap

11.29B

Low

58.960

Amount

50.92M

EV/EBITDA(TTM)

42.85

Total Shares

185.43M

10.35B

EV/OCF(TTM)

37.88

P/S(TTM)

21.20

Doximity, Inc. provides a digital platform for the United States medical professionals. It offers marketing, hiring, and workflow solutions to pharmaceutical manufacturers, health systems, medical recruiting firms, and other healthcare companies. Its marketing solutions enable its pharmaceutical and health system customers to get the right content, services, and peer connections to the right medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms, enabling them to identify, connect with, and hire from its network of both active and passive medical professional candidates, who might otherwise be missed through traditional recruiting channels. Its workflow solutions include its telehealth, on-call scheduling, and AI-powered workflow tools, are designed to help clinicians streamline their clinical workflow, reduce their administrative burden, and connect with patients and colleagues.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q2

FY2026Q1

183.11M

+8.6%

0.450

-0.09%

150.26M

+9.82%

0.347

+15.58%

139.54M

+10.15%

0.307

+9.67%

Estimates Revision

The market is revising Downward the revenue expectations for Doximity, Inc. (DOCS) for FY2026, with the revenue forecasts being adjusted by -2.11% over the past three months. During the same period, the stock price has changed by 13.07%.

Revenue Estimates for FY2026

Revise Downward

-2.11%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+1.96%

In Past 3 Month

Stock Price

Go Up

+13.07%

In Past 3 Month

16 Analyst Rating

3.41% Upside

Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 61.27 USD with a low forecast of 50.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

9 Hold

0 Sell

Moderate Buy

3.41% Upside

Current: 59.250

Low

50.00

Averages

61.27

High

80.00

3.41% Upside

Current: 59.250

Low

50.00

Averages

61.27

High

80.00

Truist

Jailendra Singh

Hold

maintain

$52 -> $61

2025-07-17

New

Reason

Truist

Jailendra Singh

Price Target

$52 -> $61

2025-07-17

New

maintain

Hold

Reason

Truist analyst Jailendra Singh raised the firm's price target on Doximity to $61 from $52 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 results for Health Care IT / Digital Health sector names. Despite the strong YTD outperformance in shares, investor sentiment still remains relatively mixed, with the interest level from long-onlies/generalist investors seen as "relatively selective", the analyst tells investors in a research note. HCIT space has also benefited from the lack of direct tariff exposure and other macro uncertainty as well as renewed capital market activity, the firm added.

Evercore ISI

Elizabeth Anderson

In Line -> Outperform

upgrade

$50 -> $70

2025-07-09

Reason

Evercore ISI

Elizabeth Anderson

Price Target

$50 -> $70

2025-07-09

upgrade

In Line -> Outperform

Reason

Evercore ISI analyst Elizabeth Anderson upgraded Doximity to Outperform from In Line with a price target of $70, up from $50. The firm believes the company's fiscal 2026 guidance is conersvartive. Doximity's formulary business is likely to grow at least mid-single-digits in fiscal 2026, which would allow the remaining pharma business to grow just 2% and still hit the current midpoint of the outlook, the analyst tells investors in a research note. Evercore believes Doximity has an "enviable model" with very high incremental EBITDA margins when revenue outperforms expectations.

BofA

Anna Bryson

Neutral

maintain

$55 -> $62

2025-06-25

Reason

BofA

Anna Bryson

Price Target

$55 -> $62

2025-06-25

maintain

Neutral

Reason

BTIG

David Larsen

Neutral -> Buy

upgrade

$80

2025-06-02

Reason

BTIG

David Larsen

Price Target

$80

2025-06-02

upgrade

Neutral -> Buy

Reason

BTIG analyst David Larsen upgraded Doximity to Buy from Neutral with an $80 price target. Although there is macro uncertainty with respect to the biopharma industry, including the risk of tariffs, ongoing drug pricing reform, the Inflation Reduction Act, and Medicare rate pressures, demand for high-quality, precise, software-as-a-service commercialization efforts will continue to rise, the analyst tells investors in a research note. The firm believes Doximity's recent fiscal 2026 guidance is likely conservative and accounts for macro risks. The company has $900M of cash, no debt, and high gross and EBITDA margins relative to the group, contends BTIG.

JPMorgan

Neutral

downgrade

$63 -> $60

2025-05-27

Reason

JPMorgan

Price Target

$63 -> $60

2025-05-27

downgrade

Neutral

Reason

JPMorgan lowered the firm's price target on Doximity to $60 from $63 and keeps a Neutral rating on the shares. The firm updated the company's model.

Baird

Outperform

NULL

downgrade

$87 -> $65

2025-05-20

Reason

Baird

Price Target

$87 -> $65

2025-05-20

downgrade

Outperform

NULL

Reason

Baird lowered the firm's price target on Doximity to $65 from $87 and keeps an Outperform rating on the shares.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Doximity Inc (DOCS.N) is 41.60, compared to its 5-year average forward P/E of 58.76. For a more detailed relative valuation and DCF analysis to assess Doximity Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

58.76

Current PE

41.60

Overvalued PE

107.09

Undervalued PE

10.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

38.42

Current EV/EBITDA

30.44

Overvalued EV/EBITDA

68.91

Undervalued EV/EBITDA

7.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

17.47

Current PS

17.99

Overvalued PS

27.05

Undervalued PS

7.90